BioCentury | Sep 1, 2020
Deals

Gilead deal clears path for Jounce to advance immuno-oncology programs

Via a deal with Gilead yielding $120 million in upfront cash for rights to a preclinical oncology program, Jounce will extend its cash runway into 2023 as it presses forward with a lead program on...
BioCentury | Aug 20, 2020
Finance

Inhibrx, Harmony debut on NASDAQ as JW, Harbour line up on HKEX

Investor appetite for biotech is going strong in both the U.S. and Hong Kong, with Inhibrx and Harmony posting double-digit gains Wednesday after pricing upsized NASDAQ IPOs late Tuesday, and JW and Harbour lining up...
BioCentury | Jul 21, 2020
Product Development

Amplyx’s first-in-class antifungal heads for a head-to-head study

Following a positive Phase II readout, Amplyx plans to take lead candidate fosmanogepix into a Phase III head-to-head trial against echinocandins as first-line treatment for invasive Candida infections. Echinocandins are standard of care in the...
BioCentury | Jul 11, 2020
Finance

Harbour continues flurry of deals with $102.8M series C round

On the back of multiple COVID-19 mAb deals and a $75 million series B+ round closed in March, Harbour BioMed has raised another $102.8 million via a series C round led by Hudson Bay Capital....
BioCentury | Jun 25, 2020
Deals

June 24 Quick Takes: CSL pays $450M for uniQure’s hemophilia gene therapy; plus Merck-Yumanity, Editas, Compass-Olivia, Century-Empirica, Tetraphase-La Jolla

CSL gets global rights to uniQure gene therapy CSL Ltd. (ASX:CSL) is paying $450 million up front for an exclusive, worldwide license to commercialize etranacogene dezaparvovec (AMT-061) from uniQure N.V. (NASDAQ:QURE), which is also eligible...
BioCentury | Jun 16, 2020
Product Development

Bit Bio scales up cell programming ambitions with $41.5M from blue-chip investors

With a $41.5 million series A round led by Rick Klausner, Arch and Foresite, Bit Bio is moving beyond commercializing a handful a cell types to the moonshot goal of generating every cell type in...
BioCentury | May 19, 2020
Finance

May 19 Quick Takes: Cowen closes $493M fund; plus Guangzhou BeBetter, Fountain Therapeutics, Amplyx, ChromaCode, Applied Molecular

Cowen raises $493M life sciences fund Cowen Healthcare Investments closed its third life sciences fund at $493 million to invest in biopharma, diagnostics and digital health. LPs in Cowen Healthcare Investments III include institutional investors,...
BioCentury | Apr 18, 2020
Finance

Venture funding back on track as China’s investors recalibrate

After nearly grinding to a halt in the first two months of 2020, venture money has begun to flow to China’s biotechs as investors adjust to investing amid the COVID-19 outbreak. A spate of venture...
BioCentury | Apr 17, 2020
Product Development

Seeking safe microbiome therapies amid COVID-19 crisis

Reports that the novel coronavirus lingers in the stools of COVID-19 patients has put a spotlight on the safety risks of gut microbiome therapies. As researchers sort out whether the virus is capable of fecal...
BioCentury | Apr 6, 2020
Deals

Vir speeding COVID-19 mAbs into Phase II with $250M GSK investment

A $250 million investment by GlaxoSmithKline will put the clinical trial expertise and regulatory acumen of one of the leading anti-infective drug companies behind Vir’s effort to bring an antibody therapy to fight against COVID-19,...
Items per page:
1 - 10 of 714
BioCentury | Sep 1, 2020
Deals

Gilead deal clears path for Jounce to advance immuno-oncology programs

Via a deal with Gilead yielding $120 million in upfront cash for rights to a preclinical oncology program, Jounce will extend its cash runway into 2023 as it presses forward with a lead program on...
BioCentury | Aug 20, 2020
Finance

Inhibrx, Harmony debut on NASDAQ as JW, Harbour line up on HKEX

Investor appetite for biotech is going strong in both the U.S. and Hong Kong, with Inhibrx and Harmony posting double-digit gains Wednesday after pricing upsized NASDAQ IPOs late Tuesday, and JW and Harbour lining up...
BioCentury | Jul 21, 2020
Product Development

Amplyx’s first-in-class antifungal heads for a head-to-head study

Following a positive Phase II readout, Amplyx plans to take lead candidate fosmanogepix into a Phase III head-to-head trial against echinocandins as first-line treatment for invasive Candida infections. Echinocandins are standard of care in the...
BioCentury | Jul 11, 2020
Finance

Harbour continues flurry of deals with $102.8M series C round

On the back of multiple COVID-19 mAb deals and a $75 million series B+ round closed in March, Harbour BioMed has raised another $102.8 million via a series C round led by Hudson Bay Capital....
BioCentury | Jun 25, 2020
Deals

June 24 Quick Takes: CSL pays $450M for uniQure’s hemophilia gene therapy; plus Merck-Yumanity, Editas, Compass-Olivia, Century-Empirica, Tetraphase-La Jolla

CSL gets global rights to uniQure gene therapy CSL Ltd. (ASX:CSL) is paying $450 million up front for an exclusive, worldwide license to commercialize etranacogene dezaparvovec (AMT-061) from uniQure N.V. (NASDAQ:QURE), which is also eligible...
BioCentury | Jun 16, 2020
Product Development

Bit Bio scales up cell programming ambitions with $41.5M from blue-chip investors

With a $41.5 million series A round led by Rick Klausner, Arch and Foresite, Bit Bio is moving beyond commercializing a handful a cell types to the moonshot goal of generating every cell type in...
BioCentury | May 19, 2020
Finance

May 19 Quick Takes: Cowen closes $493M fund; plus Guangzhou BeBetter, Fountain Therapeutics, Amplyx, ChromaCode, Applied Molecular

Cowen raises $493M life sciences fund Cowen Healthcare Investments closed its third life sciences fund at $493 million to invest in biopharma, diagnostics and digital health. LPs in Cowen Healthcare Investments III include institutional investors,...
BioCentury | Apr 18, 2020
Finance

Venture funding back on track as China’s investors recalibrate

After nearly grinding to a halt in the first two months of 2020, venture money has begun to flow to China’s biotechs as investors adjust to investing amid the COVID-19 outbreak. A spate of venture...
BioCentury | Apr 17, 2020
Product Development

Seeking safe microbiome therapies amid COVID-19 crisis

Reports that the novel coronavirus lingers in the stools of COVID-19 patients has put a spotlight on the safety risks of gut microbiome therapies. As researchers sort out whether the virus is capable of fecal...
BioCentury | Apr 6, 2020
Deals

Vir speeding COVID-19 mAbs into Phase II with $250M GSK investment

A $250 million investment by GlaxoSmithKline will put the clinical trial expertise and regulatory acumen of one of the leading anti-infective drug companies behind Vir’s effort to bring an antibody therapy to fight against COVID-19,...
Items per page:
1 - 10 of 714